Therefore our high-jumping analysis correctly suggested MKRN1 as a new T2D target before it was explicitly stated, and before the suggestion that glycemic regulation by AMPK could be a therapy for T2D [62]. This evidence concerns the gene MKRN1 and type 2 diabetes mellitus.